Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)

BACKGROUND: Despite standard treatments including chemoradiotherapy with temozolomide (TMZ) (STUPP protocol), the prognosis of glioblastoma patients remains poor. AGuIX nanoparticles have a high radiosensitizing potential, a selective and long-lasting accumulation in tumors and a rapid renal elimina...

Descripción completa

Detalles Bibliográficos
Autores principales: Thivat, Emilie, Casile, Mélanie, Moreau, Juliette, Molnar, Ioana, Dufort, Sandrine, Seddik, Khalide, Le Duc, Géraldine, De Beaumont, Olivier, Loeffler, Markus, Durando, Xavier, Biau, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105392/
https://www.ncbi.nlm.nih.gov/pubmed/37060055
http://dx.doi.org/10.1186/s12885-023-10829-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105392/
https://www.ncbi.nlm.nih.gov/pubmed/37060055
http://dx.doi.org/10.1186/s12885-023-10829-y

Ejemplares similares